Flagship W4 Earbuds Become the Most Accurate Interpreter Device Ever Released

LAS VEGAS, Jan. 5, 2026 /PRNewswire/ — Timekettle, the global leader in AI-powered cross-language communication, today announces a major system-wide upgrade that redefines what real-time translation can achieve. Central to this leap forward is Timekettle’s new SOTA (State of the Art) Translation Engine Selector, a behind-the-scenes but transformative capability that dynamically identifies the optimal translation model for each language pair and conversational scenario in real time.

While invisible to the user, the impact is unmistakable: the fastest, most precise, and most natural translations Timekettle has ever delivered, regardless of accent, grammar structure, or speaking style. This upgrade arrives alongside an enhanced Bone-Conduction & Hybrid Algorithm, now offering even cleaner, more accurate voice capture by improving the purity of the user’s vocal signal before it reaches the translation pipeline.

Together, these advancements make the flagship W4 Interpreter Earbuds the most accurate in company history, surpassing the already industry-leading performance showcased at IFA 2025 that leaves its competition lost in translation. 

Since, hearing is believing, this innovation along with the full Timekettle portfolio can be experienced throughout CES at the Timekettle booth [LVCC, North Hall — 9163].

A Leap Forward in Machine Understanding: SOTA Translation Engine Selector

Different language pairs behave like entirely different systems—English to Korean follows different logic than German to English; Spanish to Chinese requires different segmentation, prediction, and contextual inference than Japanese to French. Timekettle’s SOTA Translation Engine Selector resolves this fundamental problem by:

• Detecting the language pair and context in real time
• Selecting the specialized AI engine best suited to that specific pair
• Optimizing accuracy, fluency, and naturalness for each exchange

This is equivalent to assigning a “native specialist” to every conversation. This capability is made possible by Timekettle’s advanced Large Language Model and the ongoing evolution of its Babel OS platform now updated with new machine-learning layers trained on millions of linguistic samples.

The result: translations that sound less like a machine “attempting” to interpret—and more like a system that genuinely understands the intent, tone, and structure of what is being said. To Timekettle users, this means that no matter what languages they speak, Timekettle can always match them with the world’s best translation engines to serve their needs, enabling them to enjoy the most accurate cross-language communication experience without fear, awkwardness, or hesitation; to truly express themselves boldly and communicate naturally.

Next-Generation Bone-Conduction & Hybrid Algorithm: Superior Voice Capture for Superior Accuracy

Building on its proprietary bone-voiceprint sensor technology, the enhanced 2026 algorithm upgrade extracts cleaner vocal vibrations to improve signal purity, isolates noise more effectively in chaotic environments, and more accurately identifies speakers during multi-voice conversations. These improvements work together to deliver far clearer acoustic input—the foundation of any high-precision translation—and ensure that the system captures meaning with exceptional fidelity. Because AI translation quality is only as strong as the audio it receives, this upgrade dramatically elevates performance across business meetings, travel scenarios, classrooms, and multilingual events.

Rolling Out Across the Entire Timekettle Portfolio

Beginning in early 2026, the SOTA Translation Engine Selector, updated Hybrid Algorithm, and extended Babel OS enhancements will roll out across the full Timekettle product family, including:

• W4 Interpreter Earbuds: Now the most accurate consumer translation earbuds Timekettle has produced
• W4 Pro: Elevated for professional meetings and enterprise use
• T1 AI Translator: The world’s fastest offline translator now combines Edge AI with the SOTA Engine Selector to boost accuracy beyond its already industry-leading offline performance and ultra-fast 0.2-second response time.
• WT2 Edge, M3 Earbuds, and X1 Interpreter Hub: Each gaining improvements in context prediction, segmentation, and tonal translation

Shared Capabilities Across the Timekettle Portfolio

Across its expanding lineup of earbuds and handheld translators, Timekettle delivers a unified experience built around seamless, natural, real-time communication. All devices support instant translation across 43 languages and 96 accents, covering more than 95% of global regions to enable smooth, uninterrupted conversations anywhere in the world. Users benefit from all-day practicality as well, with long-lasting battery performance designed for travel, business, and extended multilingual interactions.

Timekettle’s conversation modes are consistent across the portfolio, offering flexible ways to communicate in different settings. One-on-One Mode allows two people to share earbuds for fluid, face-to-face dialogue. Listen & Play Mode records spoken audio through the app and provides translations that can be reviewed or replayed later. Speak Mode enables users to talk into their device and have translated speech broadcast clearly through the phone’s speaker, ideal for group discussions, classroom settings, tours, or presentations.

Whether using earbuds like the W4 or handheld devices such as the T1, the Timekettle ecosystem is designed to make multilingual communication effortless, intuitive, and adaptable to nearly any scenario.

“Accuracy is the result of perfect collaboration between hardware and software,” said Leal Tian, Founder & CEO of Timekettle. “With the introduction of our SOTA Translation Engine Selector and the next-generation bone-conduction algorithm, we’ve elevated that collaboration to a new level. W4 becomes the most accurate interpreter device we’ve ever created—and this upgrade strengthens every product across our portfolio.”

Availability

The 2026 SOTA Translation Engine Selector upgrade and enhanced Hybrid Algorithm will begin rolling out via over-the-air updates across supported Timekettle devices starting January 2026, with the full portfolio supported throughout Q1. The Timekettle portfolio is available to buy at www.timekettle.co and Amazon. Prices include W4 Interpreter Earbuds ($349), W4 Pro ($449), T1 AI Translator ($299.99), WT2 Edge ($349.99), M3 Earbuds ($149.99), and X1 Interpreter Hub ($699.99).  

About Timekettle

Since 2016, Timekettle has led innovation in AI-driven cross-language communication, with award-winning devices used by travelers, businesses, educators, and multilingual teams worldwide. Its products—including the W4 and W4 Pro Interpreter Earbuds, WT2 Edge/W3 series, X1 Interpreter Hub, and T1 AI Translator—deliver seamless, natural, and secure communication across nearly all global regions.

DUBAI, UAE, Jan. 5, 2026 /PRNewswire/ — Meraas, a member of Dubai Holding Real Estate, has unveiled an expanded residential masterplan for Dubai Design District (d3), transforming the district into one of Dubai’s most desirable creative-led waterfront neighbourhoods.

Design District Masterplan 1

Located between Downtown Dubai and Dubai Creek Harbour, the enhanced masterplan spans 18 million sqft of land. Designed and delivered by Meraas, the neighbourhood blends residential, cultural, retail and hospitality experiences, reinforcing Dubai’s ambition to strengthen its position as a global centre for design, innovation and culture in line with the Dubai Economic Agenda D33.

A defining feature of the new masterplan is the Design Line, a fully shaded, pedestrian-first spine that seamlessly connects the entire district. Activated through public art, creative installations, community spaces and landscaped green corridors, it will support walkable, human-centric living while strengthening d3’s identity as one of Dubai’s most design-forward urban neighbourhoods.

Five distinct areas will shape the character of the new neighbourhood. Along the canal, the first will introduce contemporary residences and boutique hospitality set against an activated waterfront promenade. The urban core will unite residential offerings with curated retail and dining, integrated with d3’s established global creative ecosystem. A third area will become the cultural heart of the community, featuring performance venues and mid-rise residences overlooking the d3 Bowl. Another will offer a wellness-focused residential setting defined by parks, sports facilities and a mangrove-inspired landscape. The final area will become a centre for creativity, with galleries, studios and loft-style spaces designed to support collaboration, creativity and artistic production.

Khalid Al Malik, Chief Executive Officer of Dubai Holding Real Estate, said: “Expanding the Dubai Design District masterplan into a fully integrated creative neighbourhood is a significant step in advancing the ambitions of the Dubai Economic Agenda D33. This development strengthens Dubai Design District’s position as a global benchmark for design-focused urban living and reaffirms Dubai’s status as a destination of choice for long-term investment, talent and innovation.”

With its expanded vision, new residential offering and distinctive creative identity, the enhanced d3 masterplan will establish the district as one of Dubai’s most inspiring and globally relevant neighbourhoods – a place where creativity shapes everyday life and where the world’s creative community can truly belong.

Click here to watch the video

Design District Masterplan 2

Design District Masterplan 3

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors.

In December 2025, Kelun-Biotech and Crescent Biopharma, Inc. (“Crescent”) entered into a strategic collaboration for SKB105/CR-003 and SKB118 (a PD-1 x VEGF bispecific antibody, also known as CR-001). Under the collaboration, Kelun-Biotech granted Crescent exclusive rights to research, develop, manufacture and commercialize SKB105/CR-003 in the United States, Europe and all other markets outside of Greater China. In addition, Crescent granted Kelun-Biotech exclusive rights to research, develop, manufacture and commercialize SKB118/CR-001 in Greater China. The IND application for SKB118/CR-001 has been cleared by the U.S. Food and Drug Administration (FDA) with a global Phase I/II clinical trial for the treatment of advanced solid tumors is set to commence shortly. Kelun-Biotech plans to submit an IND application for SKB118/CR-001 to the Center for Drug Evaluation of the National Medical Products Administration of China in the near future.

About SKB105 (also known as CR-003)

SKB105 is a differentiated ADC targeting ITGB6 with a topoisomerase I inhibitor payload. ITGB6 is overexpressed in many solid tumors, but shows minimal to no expression in most normal tissues, thereby potentially reducing the risk of systemic toxicity and off-target effects. SKB105 incorporates proprietary Kthiol^® irreversible conjugation technology, linking an anti-ITGB6 fully human Immunoglobulin G1 (IgG1) monoclonal antibody (mAb) to a clinically validated cleavable linker. This design aims to enhance stability and tumor-specific payload delivery while reducing adverse effects. In preclinical models, SKB105 demonstrated a favorable efficacy, safety, and pharmacokinetic (PK) profile.

About SKB118(also known as CR-001)

SKB118/CR-001 is a tetravalent bispecific antibody being developed for the treatment of solid tumors that combines two complementary, validated mechanisms in oncology via a blockade of PD-1 and VEGF. PD-1 checkpoint inhibition is aimed at restoring T cells’ ability to recognize and destroy tumor cells, and blocking VEGF is intended for reducing blood supply to tumor cells and inhibiting tumor growth. In preclinical studies, SKB118/CR-001 demonstrated cooperative pharmacology with increased binding to PD-1 and signal blockade in the presence of VEGF as well as robust anti-tumor activity. SKB118/CR-001’s anti-VEGF activity may also normalize the vasculature at the tumor site, which has the potential to improve the localization and effectiveness of combination therapies, particularly in conjunction with ADCs. 

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

DALLAS, Jan. 5, 2026 /PRNewswire/ — Cango Inc. (NYSE: CANG) (“Cango” or the “Company”), a leading Bitcoin miner leveraging its global operations to develop an integrated energy and AI compute platform, today published its Bitcoin production and mining operations update for December 2025.

Bitcoin Mining Production and Mining Operations Update for December 2025

Paul Yu, CEO and Director of Cango, commented, “Throughout 2025, Cango delivered strong and consistent operational growth. In December, due to favorable network difficulty adjustments, we maintained stable operating hashrate levels and achieved higher daily Bitcoin production, bringing our total Bitcoin holdings to 7,528.3 BTC. Additionally, in late December, a major shareholder decided to increase its investment in Cango with a US$10.5 million commitment, which expected to close in January 2026, representing a powerful vote of confidence in our strategic roadmap. This commitment will enable us to drive greater Bitcoin mining efficiency, and accelerate the parallel development of our energy and AI compute platform in 2026.”

About Cango Inc.

Cango Inc. (NYSE: CANG) is a Bitcoin mining company with a vision to establish an integrated, global infrastructure platform capable of powering the future digital economy. The Company’s mining operations span over 40 sites across North America, the Middle East, South America, and East Africa.

Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through AutoCango.com. 

For more information, please visit: www.cangoonline.com.

Investor Relations Contact
Juliet Ye, Head of Communications
Cango Inc.
Email: ir@cangoonline.com 

Christensen Advisory
Tel: +852 2117 0861
Email: cango@christensencomms.com

DUBAI, UAE, Jan. 5, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has launched a fully sponsored market literacy education initiative aimed at supporting financial literacy and responsible market understanding among Sri Lanka-based creators, in partnership with Mastering the Markets.

The online initiative is designed to upskill creators by providing a structured foundation in how financial markets operate, with an emphasis on accurate and responsible financial communication. Selected participants will receive access to a structured 10-week course covering market structure, technical analysis fundamentals, risk awareness, and disciplined decision-making.

Creators are selected through an application-based competition to participate in the fully sponsored market education initiative focused on foundational market knowledge and responsible financial communication.

The curriculum covers core principles of technical analysis and market behavior, including market structure, price action, trends, support and resistance, and risk management. The initiative is educational in nature and does not constitute financial, investment, or trading advice.

While certain examples within the course may reference digital asset markets, the analytical frameworks taught are broadly applicable across global financial markets. The program is intended to help creators develop a clearer understanding of market behavior and communicate financial concepts clearly and responsibly to their audiences.

“This structured 10-week program is designed to help creators strengthen their foundational market knowledge and communicate responsibly,” said David Bird, Founder & Chief Education Officer at Mastering the Markets. “By focusing on strong foundations and disciplined thinking, we help people build the knowledge and confidence needed to engage with markets responsibly and over the long term.”

“Education plays an important role in how people engage with financial markets,” said Nazar Tymoshchuk, Bybit’s Mini-Global Regional Manager. “This initiative supports structured learning by giving creators access to a clear, curriculum-based foundation that can be communicated in an accessible and responsible way.”

The initiative is open to Sri Lankan key opinion leaders who demonstrate a commitment to educating themselves and their communities. By combining foundational market education with exposure to both traditional financial markets and digital asset concepts, participants gain a broader educational framework for understanding global market behavior.

Upon completion of the course, participants will gain a clearer understanding of market dynamics, technical frameworks, and how structured market analysis methodologies are applied. The initiative aims to support the creation of more educational, accurate, and responsible financial content within Sri Lanka’s creator community.

Following earlier community-focused initiatives in Sri Lanka, the program reflects Bybit’s continued investment in education-focused engagement through partnerships with established market educators.

Sri Lankan creators interested in participating may submit their details through the official application form. Shortlisted participants will be contacted separately. More information about the initiative is available here.

#Bybit / #TheCryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company,” 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱^®) in combination with MSD’s anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA^®[1]) was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS)≥1% and are EGFR-negative and ALK-negative. 

BTD is granted for treatment regimens that provide effective treatment or prevention for conditions with no currently available therapy, or that demonstrate significant clinical advantages over currently available treatments. For drugs included in the breakthrough therapy process, if relevant conditions are met, applications for conditional approval and priority review and approval can be submitted when applying for marketing authorization.

Previously, the company announced that results from the Phase III clinical trial of OptiTROP-Lung05, evaluating sac-TMT in combination with pembrolizumab as first-line treatment for PD-L1-positive NSCLC, demonstrated a statistically significant and clinically meaningful improvement in its primary endpoint of progression-free survival (PFS). A positive trend was also observed in overall survival (OS). OptiTROP-Lung05 is the first Phase III study of an immunotherapy and ADC combination to meet its primary endpoint in the first-line treatment of NSCLC. Granting of BTD for the first-line treatment of PD-L1-positive NSCLC indication offers pathways to expedite the review and potential approval process of sac-TMT for this indication.

To date, sac-TMT has received five BTDs for:

• locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022;
• locally advanced or metastatic EGFR-mutant NSCLC after progression on EGFR-TKI therapy in January 2023;
• locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023;
• first-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024;
• In combination with anti-PD-L1 monoclonal antibody tagitanlimab for the first-line treatment of locally advanced or metastatic non-squamous NSCLC without actionable genomic alterations in June 2025.

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, three indications for sac-TMT have been approved and marketed in China for: EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; Unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy. The first two indications listed above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinical benefits to a greater number of cancer patients.

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. In addition, the sNDA for sac-TMT for second-line and above treatment of HR+/HER2- BC was accepted by the Center for Drug Evaluation of the National Medical Products Administration, and was included in the priority review and approval process.

As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.